a 2023

Foxo1-Rictor axis mediates adaptive increase in Akt activity and cell survival during BCR inhibitor therapy in chronic lymphocytic leukemia.

HLAVÁČ, Kryštof, Laura ONDRIŠOVÁ, Václav ŠEDA, Eva HOFERKOVÁ, G. CHIODIN et. al.

Basic information

Original name

Foxo1-Rictor axis mediates adaptive increase in Akt activity and cell survival during BCR inhibitor therapy in chronic lymphocytic leukemia.

Authors

HLAVÁČ, Kryštof, Laura ONDRIŠOVÁ, Václav ŠEDA, Eva HOFERKOVÁ, G. CHIODIN, Lenka KOŠŤÁLOVÁ, Gabriela MLADONICKÁ PAVLASOVÁ, Daniel FILIP, Pedro FARIA ZENI, Jan OPPELT, Anna PANOVSKÁ, Karla PLEVOVÁ, Šárka POSPÍŠILOVÁ, M. ŠIMKOVIČ, F. VRBACKÝ, Daniel LYSÁK, SM. FERNANDES, MS. DAVIDS, A. MAIQUES-DIAZ, S. CHARALAMPOPOULOU, I. MARTIN-SUBERO, JR. BROWN, Michael DOUBEK, Francesco FORCONI, Jiří MAYER and Marek MRÁZ

Edition

Czech Annual Cancer Research Meeting, Olomouc, 2023

Other information

Language

English

Type of outcome

Konferenční abstrakta

Country of publisher

Czech Republic

Confidentiality degree

is not subject to a state or trade secret

References:

URL

Organization

Středoevropský technologický institut – Repository – Repository

Keywords in English

BCR inhibitors; CLL; PI3K-Akt activation

Links

LX22NPO5102, research and development project. MUNI/A/1224/2022, interní kód Repo. NV18-03-00054, research and development project. 802644, interní kód Repo.
Changed: 25/3/2024 03:21, RNDr. Daniel Jakubík

Abstract

V originále

Genetic resistance mechanisms to BCR inhibitors in CLL have been extensively described, but it remains unclear whether non-genetic adaptation might exist in CLL cells allowing for lasting lymphocytosis or resistance. We focused on the possible role of the Akt pathway in adapting to BCR inhibitors since, in mouse models, PI3K-Akt activation is the only known factor that rescues the apoptosis induced by BCR deletion in mature B cells.
Displayed: 17/6/2025 07:37